Genetics of Hypertension Associated Treatment (GenHAT) Study, Genomic Background of Blood Pressure Response to Treatment in African Americans

Request Access

Anthropometry (3)

BLBMI - Baseline body mass index (phv00495636.v1.p1)
BLHGT - Height at baseline (phv00495640.v1.p1)
BLWGT - Weight at baseline (phv00495639.v1.p1)

Biomarkers (45)

ACHOL - Baseline total cholesterol (phv00495668.v1.p1)
AFGLUC - Baseline fasting serum glucose (phv00495661.v1.p1)
AFTRIG - Baseline fasting triglycerides (phv00495672.v1.p1)
AHDL - Baseline HDL-C (phv00495669.v1.p1)
ALDL - Baseline LDL-C (phv00495670.v1.p1)
APOTAS - Baseline serum potassium (phv00495608.v1.p1)
ATRIG - Baseline triglycerides (phv00495671.v1.p1)
BLGFR - Baseline estimated glomerular filtration rate (phv00495654.v1.p1)
CHOLM24 - Cholesterol at 24 months (phv00495673.v1.p1)
CHOLM48 - Cholesterol at 48 months (phv00495674.v1.p1)
CHOLM72 - Cholesterol at 72 months (phv00495675.v1.p1)
DBPM12 - DBP at 12 months (phv00495646.v1.p1)
DBPM24 - DBP at 24 months (phv00495647.v1.p1)
DBPM36 - DBP at 36 months (phv00495648.v1.p1)
DBPM48 - DBP at 48 months (phv00495649.v1.p1)
DBPM60 - DBP at 60 months (phv00495650.v1.p1)
DBPM72 - DBP at 72 months (phv00495651.v1.p1)
DBPV6MO - DBP at 6 months (phv00495645.v1.p1)
FGLUCM24 - Fasting serum glucose at 24 months (phv00495663.v1.p1)
FGLUCM48 - Fasting serum glucose at 48 months (phv00495664.v1.p1)
FGLUCM72 - Fasting serum glucose at 72 months (phv00495665.v1.p1)
FTRIGM24 - Fasting triglycerides at 24 months (phv00495676.v1.p1)
FTRIGM48 - Fasting triglycerides at 48 months (phv00495677.v1.p1)
FTRIGM72 - Fasting triglycerides at 72 months (phv00495678.v1.p1)
GFRM12 - Estimated glomerular filtration rate at 12 months (phv00495655.v1.p1)
GFRM24 - Estimated glomerular filtration rate at 24 months (phv00495656.v1.p1)
GFRM48 - Estimated glomerular filtration rate at 48 months (phv00495657.v1.p1)
GFRM72 - Estimated glomerular filtration rate at 72 months (phv00495658.v1.p1)
LVHECG - Left ventricular hypertrophy on ECG (phv00495705.v1.p1)
M13POTAS - Serum potassium measure month 1-3 (phv00495609.v1.p1)
POTASM12 - Serum potassium at 12 months (phv00495610.v1.p1)
POTASM24 - Serum potassium at 24 months (phv00495611.v1.p1)
POTASM48 - Serum potassium at 48 months (phv00495612.v1.p1)
POTASM72 - Serum potassium at 72 months (phv00495613.v1.p1)
REND - End-stage renal disease- dialysis, renal transplant, or death (phv00495720.v1.p1)
SBP_change6 - Change in SBP from baseline to 6 months (phv00495629.v1.p1)
SBPM12 - SBP at 12 months (phv00495623.v1.p1)
SBPM24 - SBP at 24 months (phv00495624.v1.p1)
SBPM36 - SBP at 36 months (phv00495625.v1.p1)
SBPM48 - SBP at 48 months (phv00495626.v1.p1)
SBPM60 - SBP at 60 months (phv00495627.v1.p1)
SBPM72 - SBP at 72 months (phv00495628.v1.p1)
SBPV6MO - SBP at 6 months (phv00495622.v1.p1)
V2DBP - Average DBP at visit 2 (phv00495644.v1.p1)
V2SBP - Average SBP at visit 2 (baseline) (phv00495621.v1.p1)

Demographics (4)

AGE - Age at baseline (phv00495632.v1.p1)
SEX - Gender (phv00495633.v1.p1)
SEX - Biological sex (phv00498376.v1.p1)
SEX - Biological sex (phv00495604.v1.p1)

Disease Events (12)

ANG - Angina (phv00495718.v1.p1)
CCHD - Combined coronary heart disease-fatal coronary heart disease, non-fatal myocardial infarction, coronary revascularization, or hopsitalized angina (phv00495709.v1.p1)
CCVD - Combined cardiovascular disease-fatal coronary heart disease, non-fatal myocardial infarction, coronary revascularization, hospitalized angina, stroke, non-hospitalized treated angina, peripheral arterial disease, fatal heart failure, hospitalized heart failure, or treated non-hospitalized heart failure (phv00495710.v1.p1)
CHDD - CHD death (phv00495725.v1.p1)
CHFDTH - Congestive heart failure death (phv00495758.v1.p1)
CRVSC - Coronary revascularization- coronary artery bypass graft, percutaneous angioplasty, insertion of stents and atherectomy (phv00495717.v1.p1)
CVDTH - Cardiovascular disease death and/or nonfatal myocardial infarction and/or nonfatal hospitalized congestive heart failure and/or nonfatal stroke (phv00495761.v1.p1)
DIABETES - Type 2 diabetes mellitus (phv00495634.v1.p1)
EP_CHD - Nonfatal MI or fatal CHD (phv00495707.v1.p1)
LEXT - Lower extremity arterial disease or revascularization or peripherial artery disease (phv00495719.v1.p1)
MAJCV - Major cardiovascular event- fatal coronary heart disease and/or non-fatal myocardial infarction (phv00495724.v1.p1)
NFMI - Nonfatal myocardial infarction (phv00495723.v1.p1)

Medications (15)

HMGCAY1 - On HMG CoA reductase inhibitor year 1 (phv00495692.v1.p1)
HMGCAY2 - On HMG CoA reductase inhibitor year 2 (phv00495693.v1.p1)
HMGCAY3 - On HMG CoA reductase inhibitor year 3 (phv00495694.v1.p1)
HMGCAY4 - On HMG CoA reductase inhibitor year 4 (phv00495695.v1.p1)
HMGCAY5 - On HMG CoA reductase inhibitor year 5 (phv00495696.v1.p1)
NHYPRY1 - Number of antihypertensive medications year 1 (phv00495683.v1.p1)
NHYPRY2 - Number of antihypertensive medications year 2 (phv00495685.v1.p1)
NHYPRY3 - Number of antihypertensive medications year 3 (phv00495687.v1.p1)
NHYPRY4 - Number of antihypertensive medications year 4 (phv00495689.v1.p1)
NHYPRY5 - Number of antihypertensive medications year 5 (phv00495691.v1.p1)
OLLMY1 - On other lipid lowering medication year 1 (phv00495697.v1.p1)
OLLMY2 - On other lipid lowering medication year 2 (phv00495698.v1.p1)
OLLMY3 - On other lipid lowering medication year 3 (phv00495699.v1.p1)
OLLMY4 - On other lipid lowering medication year 4 (phv00495700.v1.p1)
OLLMY5 - On other lipid lowering medication year 5 (phv00495701.v1.p1)

Race and Ethnicity (2)

ETHNIC - Ethnicity (phv00495638.v1.p1)
RACE - Race (phv00495637.v1.p1)

Substance Use (2)

CIGSMOKR - Current cigarette smoker (phv00495635.v1.p1)
SMOKING - Cigarette smoking (phv00495641.v1.p1)

Other (66)

AGLUC - Baseline serum glucose (phv00495662.v1.p1)
ANALYTE_TYPE - Analyte Type (phv00495617.v1.p1)
ANALYTE_TYPE - Analyte Type (phv00495765.v1.p1)
BLMEDS - Baseline medications (phv00495680.v1.p1)
BODY_SITE - Body site where sample was collected (phv00495616.v1.p1)
BODY_SITE - Body site where sample was collected (phv00495764.v1.p1)
Calling_Algorithm - Software used to make calls (phv00495767.v1.p1)
CALLING_ALGORITHM - Software used to make calls (phv00495619.v1.p1)
CHF - Congestive heart failure (phv00495708.v1.p1)
CONSENT - Consent group as determined by DAC (phv00495603.v1.p1)
DBP_change6 - Change in DBP from baseline to 6 months (phv00495652.v1.p1)
DEATH - All cause mortality (phv00495706.v1.p1)
EGFR_change12 - Change in eGFR from baseline to 12 months (phv00495659.v1.p1)
FAMILY_ID - Family ID (phv00498372.v1.p1)
FATHER - Father's GENHATID (Subject ID) (phv00498374.v1.p1)
FG_change24 - Change in fasting glucose from baseline to 24 months (phv00495666.v1.p1)
GENHATID - Subject ID (phv00495702.v1.p1)
GENHATID - Subject ID (phv00495679.v1.p1)
GENHATID - Subject ID (phv00495630.v1.p1)
GENHATID - Subject ID (phv00495667.v1.p1)
GENHATID - Subject ID (phv00495620.v1.p1)
GENHATID - Subject ID (phv00495643.v1.p1)
GENHATID - Subject ID (phv00495607.v1.p1)
GENHATID - Subject ID (phv00495653.v1.p1)
GENHATID - Subject ID (phv00495660.v1.p1)
GENHATID - Subject ID (phv00498373.v1.p1)
GENHATID - Subject ID (phv00495602.v1.p1)
GENHATID - Subject ID (phv00495605.v1.p1)
Genotyping_Platform - Genotyping platform used (phv00495766.v1.p1)
GENOTYPING_PLATFORM - Genotyping platform used (phv00495618.v1.p1)
KIDDTH - Kidney disease death (phv00495759.v1.p1)
LIPMEDS - Lipid medications in last year (phv00495681.v1.p1)
LRZGRP - Lipid Randomization Group (phv00495642.v1.p1)
MIDTH - Myocardial infarction death (phv00495754.v1.p1)
MOTHER - Mother's GENHATID (Subject ID) (phv00498375.v1.p1)
NCHDD - Non-CHD death (phv00495726.v1.p1)
NCHFDD - Non-CHF/Non-CHD death (phv00495728.v1.p1)
NCVDD - Non-CVD death (phv00495727.v1.p1)
ONCVDDTH - Other non-CVD death (phv00495760.v1.p1)
ONST1Y1 - Receiving blinded study drug year 1 (phv00495682.v1.p1)
ONST1Y2 - Receiving blinded study drug year 2 (phv00495684.v1.p1)
ONST1Y3 - Receiving blinded study drug year 3 (phv00495686.v1.p1)
ONST1Y4 - Receiving blinded study drug year 4 (phv00495688.v1.p1)
ONST1Y5 - Receiving blinded study drug year 5 (phv00495690.v1.p1)
POTAS_change1to3 - Change of potassium from baseline to measurements at month 1-3 (phv00495614.v1.p1)
RZGRP - Antihypertensive randomization group (phv00495631.v1.p1)
SAMPLE_ID - Sample ID (phv00495615.v1.p1)
SAMPLE_ID - Sample ID (phv00495763.v1.p1)
SAMPLE_ID - Sample ID (phv00495606.v1.p1)
STRDTH - Stroke death (phv00495757.v1.p1)
STROKE - Stroke (phv00495703.v1.p1)
UDTH - Unknown cause of death (phv00495762.v1.p1)
YRANG - Years to angina (phv00495743.v1.p1)
YRCCHD - Years to CCHD (phv00495734.v1.p1)
YRCCVD - Years to CCVD (phv00495735.v1.p1)
YRCHD - Years to CHD (phv00495732.v1.p1)
YRCHDD - Years to CHD death (phv00495750.v1.p1)
YRCHF - Years to CHF (phv00495733.v1.p1)
YRDEATH - Years to DEATH (phv00495730.v1.p1)
YRLEXT - Years to LEXT (phv00495744.v1.p1)
YRMAJCV - Years to MAJCV (phv00495749.v1.p1)
YRNCHDD - Years to NCHDD (phv00495751.v1.p1)
YRNCVDD - Years to NCVDD (phv00495752.v1.p1)
YRNFMI - Years to NFMI (phv00495748.v1.p1)
YRREND - Years to REND (phv00495745.v1.p1)
YRSTROKE - Years to STROKE (phv00495731.v1.p1)